Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.40 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30051153 | 0.86 | GRM5 (0.39) | GRM5DOT1L | |
| SCHEMBL24807716 | 0.82 | DPP4 (0.32) | — | |
| SCHEMBL24173326 | 0.81 | KMT2A (0.44) | GRM5 | |
| SCHEMBL30050598 | 0.80 | GRM5 (0.39) | GRM5DOT1L | |
| SCHEMBL30051312 | 0.80 | GRM5 (0.44) | GRM5DOT1LDYRK1AADORA2AADORA1 | |
| SCHEMBL23959239 | 0.80 | GRM5 (0.44) | GRM5DOT1LDYRK1AADORA2AADORA1 | |
| SCHEMBL30050420 | 0.79 | GRM5 (0.42) | GRM5DOT1LDYRK1A | |
| SCHEMBL24807701 | 0.79 | GRM5 (0.42) | GRM5DOT1LDYRK1A | |
| SCHEMBL24810325 | 0.76 | GRM5 (0.41) | GRM5DOT1LDYRK1A | |
| SCHEMBL24167925 | 0.73 | MAP4K4 (0.42) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041385-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2023-02-09 | — | — | US | disclosed |
| WO-2022269531-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022269531-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2022-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041385-A1 | HER2 MUTATION INHIBITORS | ERBB2, EGFR, ERBB3 | GRM5 2106/4885DOT1L 1501/4885DYRK1A 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.